Shareholder Alert: The Ademi Firm investigates whether RAPT Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders

Core Viewpoint - Ademi LLP is investigating RAPT for potential breaches of fiduciary duty and other legal violations related to its transaction with GSK plc [1] Group 1: Transaction Details - RAPT stockholders can choose to receive $58.00 per share, leading to an estimated total equity value of $2.2 billion [2] - RAPT insiders are set to gain significant benefits from change of control arrangements as part of the transaction [2] Group 2: Investigation Focus - The transaction agreement restricts competing offers for RAPT by imposing a substantial penalty if a competing bid is accepted [3] - The investigation will assess whether the RAPT board of directors is meeting their fiduciary responsibilities to all shareholders [3]